HBL Hadasit Bio Holdings Ltd
TASE:HDST
Net Margin
HBL Hadasit Bio Holdings Ltd
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
| Country | Company | Market Cap |
Net Margin |
||
|---|---|---|---|---|---|
| IL |
H
|
HBL Hadasit Bio Holdings Ltd
TASE:HDST
|
16.5m ILS | N/A | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
-21 040%
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
370.2B USD |
6%
|
|
| US |
U
|
US BioTec Inc
OTC:USBC
|
165.2B USD | N/A | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
158.9B USD |
19%
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
144.5B USD |
22%
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
-392%
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
101.9B USD |
32%
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
109.4B AUD |
19%
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
63.6B USD |
31%
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
60.8B USD |
-13%
|
HBL Hadasit Bio Holdings Ltd
Glance View
HBL- Hadasit Bio-Holdings Ltd. engages in investments in research and development companies in the medical and biotechnology sectors. The Company’s subsidiaries enable research and development and promote intellectual property (IP) to the medical and biotechnological industries. The firm together with its strategic partners, has established a number of start-up companies, and is assigned to commercialize that IP either through granting a product license to biotechnological or pharmaceutical companies or via the creation of a subsidiary which operates in the premise of HMO. Hadasit is equipped with resources and capabilities required for composing and conducting the pre-clinical services and clinical studies, establishing start-up companies, offering product licensing and providing international consulting services. The Company’s framework serves to address investment in early-stage biotechnological star-ups, by distributing both risk and success amongst a number of companies.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on HBL Hadasit Bio Holdings Ltd's most recent financial statements, the company has Net Margin of 0%.
You don't have any saved screeners yet